Exploiting inflammation for therapeutic gain in pancreatic cancer.

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, inflammatory signals are implicated in both tumour initiation and tumour progression. The major pathways regulating...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Pancreatic Ductal
• Share to Chemokines
• Share to Immunologic Surveillance